Impact of Non-Vitamin K Antagonist Oral Anticoagulants on Intracranial Bleeding in Asian Patients With Non-Valvular Atrial Fibrillation

DOI Web Site Web Site PubMed 被引用文献17件 参考文献40件
  • Yasaka Masahiro
    Department of Cerebrovascular Medicine and Neurology, National Hospital Organization, Kyushu Medical Center
  • Lip Gregory Y.H.
    University of Birmingham Centre for Cardiovascular Sciences, City Hospital Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University

この論文をさがす

抄録

The incidence of intracranial bleeding is known to be markedly higher in Japan and other East Asian countries than in countries outside of East Asia. Non-vitamin K antagonist oral anticoagulants (NOACs) have much lower risk of intracranial bleeding than warfarin, so we reviewed the effect of this class of drugs on intracranial bleeding in Asian patients with non-valvular atrial fibrillation (NVAF). Warfarin therapy in Asian or East Asian populations appears to be associated with lower efficacy, poorer safety and a much greater risk of intracranial bleeding when compared with non-Asian or non-East Asian groups. Reflecting the higher incidence of intracranial bleeding in Asia and East Asia, Asian physicians in charge usually keep the prothrombin time-international normalized ratio (PT-INR) lower than is the case in Western countries. Irrespective of the lower PT-INR of warfarin, the incidence of intracranial bleeding is still high in Asia and East Asia. Because each NOAC strongly reduces the incidence of intracranial bleeding when compared with warfarin, use of dabigatran, rivaroxaban, apixaban or edoxaban would seem the best option for stroke prevention when treating Asian patients, including Japanese with NVAF. (Circ J 2014; 78: 2367–2372)

収録刊行物

  • Circulation Journal

    Circulation Journal 78 (10), 2367-2372, 2014

    一般社団法人 日本循環器学会

被引用文献 (17)*注記

もっと見る

参考文献 (40)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ